Aridis Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223039521 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.00K $1.886M
YoY Change -98.14% -89.65%
Cash & Equivalents $35.00K $1.886M
Short-Term Investments
Other Short-Term Assets $3.558M $6.501M
YoY Change -45.27% 57.1%
Inventory
Prepaid Expenses
Receivables $400.0K
Other Receivables $100.0K
Total Short-Term Assets $4.110M $8.635M
YoY Change -52.4% -63.38%
LONG-TERM ASSETS
Property, Plant & Equipment $511.0K $974.0K
YoY Change -47.54% -32.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $327.0K $383.0K
YoY Change -14.62% -11.55%
Total Long-Term Assets $2.424M $3.485M
YoY Change -30.44% 39.18%
TOTAL ASSETS
Total Short-Term Assets $4.110M $8.635M
Total Long-Term Assets $2.424M $3.485M
Total Assets $6.534M $12.12M
YoY Change -46.09% -53.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.410M $4.230M
YoY Change 27.9% 59.98%
Accrued Expenses $7.691M $8.494M
YoY Change -9.45% 29.48%
Deferred Revenue $380.0K $20.39M
YoY Change -98.14% 4.1%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $831.0K
YoY Change -100.0%
Total Short-Term Liabilities $17.48M $42.28M
YoY Change -58.65% 46.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.499M
YoY Change -100.0%
Other Long-Term Liabilities $854.0K
YoY Change
Total Long-Term Liabilities $854.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.48M $42.28M
Total Long-Term Liabilities $854.0K $0.00
Total Liabilities $18.34M $47.94M
YoY Change -61.75% 58.54%
SHAREHOLDERS EQUITY
Retained Earnings -$190.4M -$189.3M
YoY Change 0.6% 20.96%
Common Stock $5.000K $2.000K
YoY Change 150.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.80M -$35.82M
YoY Change
Total Liabilities & Shareholders Equity $6.534M $12.12M
YoY Change -46.09% -53.54%

Cashflow Statement

Concept 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001614067
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
CY2023Q3 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
usd
CY2023Q3 us-gaap Capitalized Contract Cost Net Noncurrent
CapitalizedContractCostNetNoncurrent
usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
usd
CY2023Q3 ARDS Issuance Of Common Stock Upon Value Exercise Of Warrants
IssuanceOfCommonStockUponValueExerciseOfWarrants
usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
ARDS Other Comprehensive Income Industry Specific Credit Risk On Notes Payable
OtherComprehensiveIncomeIndustrySpecificCreditRiskOnNotesPayable
usd
ARDS Issuance Of Common Stock In Exchange For Debt Modification
IssuanceOfCommonStockInExchangeForDebtModification
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
ARDS Non Cash Debt Issuance Expense
NonCashDebtIssuanceExpense
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
ARDS Rightofuse Assets Obtained With Corresponding Lease Liability
RightofuseAssetsObtainedWithCorrespondingLeaseLiability
usd
ARDS Stock Issued In Exchange For Accrued Liability
StockIssuedInExchangeForAccruedLiability
usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38630
dei Entity Registrant Name
EntityRegistrantName
Aridis Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2641188
dei Entity Address Address Line1
EntityAddressAddressLine1
983 University Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Bldg. B
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Gatos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95032
dei City Area Code
CityAreaCode
(408)
dei Local Phone Number
LocalPhoneNumber
385-1742
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ARDS
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44574021 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4876000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
183000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
417000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000 usd
CY2023Q3 us-gaap Other Receivables
OtherReceivables
100000 usd
CY2022Q4 us-gaap Other Receivables
OtherReceivables
240000 usd
CY2022Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
1986000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3558000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3341000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4110000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11626000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
511000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
730000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1073000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1417000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000 usd
CY2022Q4 us-gaap Capitalized Contract Cost Net Noncurrent
CapitalizedContractCostNetNoncurrent
78000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000 usd
CY2023Q3 us-gaap Assets
Assets
6534000 usd
CY2022Q4 us-gaap Assets
Assets
14695000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5410000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2308000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7691000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9564000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
576000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
538000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
380000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20173000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
519000 usd
CY2023Q3 ARDS Notes Payables Fair Value Current
NotesPayablesFairValueCurrent
3410000 usd
CY2022Q4 ARDS Notes Payables Fair Value Current
NotesPayablesFairValueCurrent
3781000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17482000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36898000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
737000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
854000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1292000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
18336000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
38927000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44574021 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44574021 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27033532 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27033532 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170827000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166380000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7787000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5051000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190421000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195666000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11802000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-24232000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6534000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14695000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
417000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
399000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21146000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1878000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6118000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10374000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18916000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1111000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1693000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4235000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5535000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1286000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7811000 usd
us-gaap Operating Expenses
OperatingExpenses
14609000 usd
us-gaap Operating Expenses
OperatingExpenses
24451000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-869000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7412000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6537000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22573000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
31000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-267000 usd
CY2023Q3 us-gaap Other Income
OtherIncome
26000 usd
CY2022Q3 us-gaap Other Income
OtherIncome
23000 usd
us-gaap Other Income
OtherIncome
77000 usd
us-gaap Other Income
OtherIncome
68000 usd
CY2023Q3 ARDS Changes In Fair Value Of Note Payable
ChangesInFairValueOfNotePayable
-759000 usd
CY2022Q3 ARDS Changes In Fair Value Of Note Payable
ChangesInFairValueOfNotePayable
823000 usd
ARDS Changes In Fair Value Of Note Payable
ChangesInFairValueOfNotePayable
1400000 usd
ARDS Changes In Fair Value Of Note Payable
ChangesInFairValueOfNotePayable
1212000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-83000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8239000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5245000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23984000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37428943 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17701592 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35562129 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17701592 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37428943 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17701592 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47178967 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17701592 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-83000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8239000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5245000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23984000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-1261000 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-2736000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1178000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8239000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7981000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23984000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-14914000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1684000 usd
CY2023Q3 ARDS Issuance Of Common Stock In Exchange For Note Modification Value
IssuanceOfCommonStockInExchangeForNoteModificationValue
50000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200000 usd
CY2023Q3 ARDS Other Comprehensive Income Loss Tax Change In Fair Value Notes Payable
OtherComprehensiveIncomeLossTaxChangeInFairValueNotesPayable
-1261000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-83000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11802000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-27933000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
349000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8239000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-35823000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-24232000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3740000 usd
ARDS Issuance Of Common Stock Upon Value Exercise Of Warrants
IssuanceOfCommonStockUponValueExerciseOfWarrants
4000 usd
ARDS Issuance Of Common Stock In Exchange For Note Modification Value
IssuanceOfCommonStockInExchangeForNoteModificationValue
50000 usd
ARDS Other Comprehensive Income Loss Tax Change In Fair Value Notes Payable
OtherComprehensiveIncomeLossTaxChangeInFairValueNotesPayable
-2736000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
655000 usd
us-gaap Net Income Loss
NetIncomeLoss
5245000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11802000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13110000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13110000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3000 usd
ARDS Adjustments To Additional Paid In Capital Stock Issued In Exchange For Accrued Liability
AdjustmentsToAdditionalPaidInCapitalStockIssuedInExchangeForAccruedLiability
107000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1161000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23984000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23984000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-35823000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-35823000 usd
us-gaap Net Income Loss
NetIncomeLoss
5245000 usd
us-gaap Net Income Loss
NetIncomeLoss
-23984000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
209000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
387000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
33000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
655000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1161000 usd
ARDS Other Comprehensive Income Industry Specific Credit Risk On Notes Payable
OtherComprehensiveIncomeIndustrySpecificCreditRiskOnNotesPayable
-2736000 usd
ARDS Issuance Of Common Stock In Exchange For Debt Modification
IssuanceOfCommonStockInExchangeForDebtModification
-50000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
3000 usd
ARDS Change In Fair Value Of Note Payable
ChangeInFairValueOfNotePayable
-1336000 usd
ARDS Change In Fair Value Of Note Payable
ChangeInFairValueOfNotePayable
1212000 usd
ARDS Non Cash Debt Issuance Expense
NonCashDebtIssuanceExpense
250000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-583000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-140000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
11000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
217000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
132000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1986000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-78000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-47000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-56000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3102000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1010000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1873000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2121000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-20530000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-628000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9328000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20570000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
14000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3794000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1485000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
450000 usd
ARDS Payment On Financing Of Insurance Premium
PaymentOnFinancingOfInsurancePremium
519000 usd
ARDS Payment On Financing Of Insurance Premium
PaymentOnFinancingOfInsurancePremium
800000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4290000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3750000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5024000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16853000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5559000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19986000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
535000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3133000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000 usd
ARDS Rightofuse Assets Obtained With Corresponding Lease Liability
RightofuseAssetsObtainedWithCorrespondingLeaseLiability
1877000 usd
ARDS Stock Issued In Exchange For Accrued Liability
StockIssuedInExchangeForAccruedLiability
107000 usd
ARDS Issuance Of Common Stock In Exchange For Debt Modifications
IssuanceOfCommonStockInExchangeForDebtModifications
50000 usd
ARDS Issuance Of Common Stock In Exchange For Debt Modifications
IssuanceOfCommonStockInExchangeForDebtModifications
107000 usd
ARDS Insurance Financing
InsuranceFinancing
519000 usd
ARDS Insurance Financing
InsuranceFinancing
935000 usd
ARDS Number Of Wholly Owned Subsidiaries Included In Consolidated Financial Statements Of Company
NumberOfWhollyOwnedSubsidiariesIncludedInConsolidatedFinancialStatementsOfCompany
2 subsidiary
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zEdbIXoJ4dK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zaX6FefGsFMk">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Such estimates include those related to the evaluation of our ability to continue as a going concern, best estimate of standalone selling price of revenue deliverables, useful life of long-lived assets, classification of deferred revenue, income taxes, assumptions used in the Black-Scholes-Merton (“BSM”) model to calculate the fair value of stock-based compensation, deferred tax asset valuation allowances, and preclinical study and clinical trial accruals. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z80QtZu6MEY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zpYthjismi74">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s cash and cash equivalents are maintained at financial institutions in the United States of America. Deposits held by these institutions may exceed the amount of insurance provided on such deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Customer Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zHGxqer20j47" title="Revenue">0.4</span> million in grant revenue from one customer during the three months ended September 30, 2023, and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember_zB2HmxbYvLQk" title="Revenue">1.5</span> million in grant revenue from three customers during the nine months ended September 30, 2023, each individually comprising <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zTcT01eBiry7" title="Concentration risk percentage">3</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLtFley6G80e" title="Concentration risk percentage">12</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuDEeYQLYns6" title="Concentration risk percentage">85</span>% of grant revenue for the nine-month period accounting for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn2cAfsHmwr" title="Concentration risk percentage">7</span>% of total revenue. The Company recognized $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember_zq0VwHbVsFbh" title="Revenue">0.4</span> million and $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember_zCON3ldK9n3e" title="Revenue">1.9</span> million in grant revenue from three customers during the three and nine months ended September 30, 2022, each individually comprising <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zO0eAEkWVpG2" title="Concentration risk percentage">27</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOGYA5Y6NbC7" title="Concentration risk percentage">34</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7HlJ74rchgg" title="Concentration risk percentage">39</span>% of grant revenue for the nine-month period accounting for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zofVDHcMHwOf" title="Concentration risk percentage">100</span>% of total revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--LicenseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zyJflPMrIFK9" title="Revenue">0</span> and $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--LicenseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zIC8VbMLVmT5" title="Revenue">19.6</span> million in license revenue (non-cash) from one customer during the three and nine months ended September 30, 2023, and <span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--LicenseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zYINFUFPYOf4" title="Revenue"><span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--LicenseMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zdPWpa2dAn14" title="Revenue">no</span></span> license revenue during the three and nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable from one customer were $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20230930__srt--MajorCustomersAxis__custom--CustomerOneMember_z4SwOsWgplmi" title="Accounts receivable">0.4</span> million as of September 30, 2023, and $<span id="xdx_905_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__srt--MajorCustomersAxis__custom--CustomerOneMember_zS8MTqcAN5N2" title="Accounts receivable">1.0</span> million as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4876000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
183000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
535000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5559000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
400000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000.0 usd
CY2023Q3 ARDS Incremental Borrowing Rate
IncrementalBorrowingRate
0.06 pure
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
227000 usd
CY2023Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0 usd
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2100000 usd
CY2023Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 usd
CY2022Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 usd
CY2023Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2100000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5100000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7800000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35600000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47200000 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-83000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-83000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8239000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8239000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5245000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5245000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23984000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-23984000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37428943 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17701592 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35562129 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17701592 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37428943 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17701592 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47178967 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17701592 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25742153 shares
CY2022Q1 ARDS Recognition Of Lease Liabilities
RecognitionOfLeaseLiabilities
2300000 usd
CY2022Q1 ARDS Recognition Of Lease Assets
RecognitionOfLeaseAssets
1900000 usd
CY2023Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
3410000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
3410000 usd
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
3781000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
3781000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
5282000 usd
CY2022 ARDS Fair Value Measurement With Unobservable Inputs Reconciliation Borrowings
FairValueMeasurementWithUnobservableInputsReconciliationBorrowings
5000000 usd
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
-1800000 usd
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
850000 usd
CY2022 us-gaap Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-500000 usd
CY2022 ARDS Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Change In Instrument Specific Credit Risk
FairValueMeasurementWithUnobservableInputsReconciliationRecurringChangeInInstrumentSpecificCreditRisk
-5051000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3781000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3781000 usd
ARDS Fair Value Measurement With Unobservable Inputs Reconciliation Borrowings
FairValueMeasurementWithUnobservableInputsReconciliationBorrowings
2500000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
-1535000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
1400000 usd
ARDS Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Change In Instrument Specific Credit Risk
FairValueMeasurementWithUnobservableInputsReconciliationRecurringChangeInInstrumentSpecificCreditRisk
-2736000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3410000 usd
CY2023Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
3400000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2759000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2773000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2248000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2043000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
511000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
730000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
58000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
123000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
205000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
383000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
81000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
81000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
68000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
64000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4000 usd
CY2023Q3 ARDS Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
7215000 usd
CY2022Q4 ARDS Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
9000000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
435000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
456000 usd
CY2023Q3 ARDS Accrued Professional Fees And Other Accrued Liabilities Current
AccruedProfessionalFeesAndOtherAccruedLiabilitiesCurrent
41000 usd
CY2022Q4 ARDS Accrued Professional Fees And Other Accrued Liabilities Current
AccruedProfessionalFeesAndOtherAccruedLiabilitiesCurrent
108000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7691000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9564000 usd
ARDS Development And License Agreements Description
DevelopmentAndLicenseAgreementsDescription
The academic COMBACTE-NET consortium partners initially pay for all costs incurred at EU clinical sites and subsequently bills the Company for 25% of such costs. Specifically, we are billed for 25% of eligible costs during the entire fiscal year six to seven months following the fiscal year. The work at these sites is performed entirely by third-party subcontractors. As such, we reimburse the 25% at the passed-through invoice amounts. There is no reimbursement for costs incurred at non-EU sites.
ARDS Gain Or Loss On Disposition
GainOrLossOnDisposition
0 usd
CY2022Q3 ARDS Debt Instrument Prepayment Interest Rate Outstanding Balance
DebtInstrumentPrepaymentInterestRateOutstandingBalance
0.015 pure
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3044000 shares
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3462000 shares
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26027542 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
396014 shares
CY2023Q1 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGranted
-54000 shares
CY2023Q1 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
113060 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
455074 shares
CY2023Q2 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGranted
-377500 shares
CY2023Q2 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
167868 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
245442 shares
CY2023Q3 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGranted
-185000 shares
CY2023Q3 ARDS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
65827 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
126269 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0443 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
185000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
616500 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.16
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
379569 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.00
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
655000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1161000 usd
CY2023Q3 ARDS Incremental Borrowing Rate
IncrementalBorrowingRate
0.06 pure
CY2022Q1 ARDS Incremental Percentage Of Discount On Borrowing Rate
IncrementalPercentageOfDiscountOnBorrowingRate
0.06 pure
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000 usd
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2300000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1073000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
576000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
854000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1430000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
158000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
646000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
666000 usd
CY2023Q3 ARDS Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
57000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1527000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
97000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1430000 usd
CY2020Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
277000 usd
CY2020Q1 ARDS Original Purchase Price
OriginalPurchasePrice
531687 usd
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0 usd
CY2022 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0 usd

Files In Submission

Name View Source Status
ards-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001493152-23-039521-index-headers.html Edgar Link pending
0001493152-23-039521-index.html Edgar Link pending
0001493152-23-039521.txt Edgar Link pending
0001493152-23-039521-xbrl.zip Edgar Link pending
ards-20230930.xsd Edgar Link pending
ards-20230930_def.xml Edgar Link unprocessable
ards-20230930_lab.xml Edgar Link unprocessable
ards-20230930_pre.xml Edgar Link unprocessable
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending